Founder and CEO addresses the Company&#39;s Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the

<p><i><strong>Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development</strong></i></p> <p><strong id="dateline">BELLEVUE, WA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 11, 2026 / </strong>OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>) today released the following letter from its Chief Executive Officer to shareholders.</p><p>Dear Shareholders,</p><p>Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.</p><p>As CEO of OSRH, I want to assure our shareholders that I remain deeply confident in the fundamental value we are building across our Company and its subsidiaries. I also want to share an important development with the market.</p><p>Without disclosing confidential information or identifying the parties involved at this stage, I can confirm that two of our subsidiaries have received inbound inquiries regarding potential out-licensing opportunities for their technologies and products. Of the two, one is at the preliminary term sheet negotiation phase while the other is in early stage. I believe both of these represent meaningful validation of the value of the intellectual property and businesses that we have worked so hard to develop.</p><p>I fully understand the significance of making this statement as the CEO of a Nasdaq-listed public company. I am making it because I believe our shareholders deserve to know that meaningful business developments are taking place behind the scenes. Time will tell, and I believe that time will tell sooner rather than later.</p><p>As we approach August 18, I respectfully ask our shareholders and long-standing supporters to remain engaged, informed, and supportive of OSRH as we work through this critical period. The Company is doing everything within its control to organically preserve its Nasdaq listing and to ensure that the substantial value being created within our subsidiaries can ultimately be reflected in the market.</p><p>I have also received many messages from shareholders asking why I have not personally purchased additional shares at the current price levels. I want to clarify this point for the market.</p><p>As the largest investor in OSRH, I have been "all in" for a very long time. Since inception, I have committed substantial personal capital through multiple rounds of financing to provide liquidity and support the continued operation of our cash-burning R&D businesses. Anyone who has built a startup from the ground up as a founder will understand what I mean when I say that I am already all in.</p><p>Our journey has never been about building value overnight. We planted the seeds, watered them, nurtured them, and continued investing in them through some extraordinarily difficult circumstances. Our subsidiaries are now entering a period in which their business development activities are accelerating, and we believe the commercial potential of these businesses will become increasingly evident.</p><p>This has undoubtedly been one of the most difficult years in our Company's history, particularly because of the pressure on our share price. But I continue to believe that, ultimately, fundamentals matter. The technologies, intellectual property, people, and businesses that we have built are real-and we intend to continue working relentlessly to unlock their value.</p><p>OSRH is guided by a seasoned management team with deep, complementary experience across biosciences, medical technology, drug development, regulatory, legal and capital markets. This team has both the capability and the resolve to steer the Company through challenging periods such as this one. We have navigated adversity before, and we are confident in our ability to do so again.</p><p>There is still uncertainty ahead, and I will not make promises about outcomes that are not yet within our control. But I can make this promise: we will continue to fight for the Company, for the businesses we have built, and for the interests of our shareholders. I have invested alongside you, I remain invested alongside you, and I remain committed to seeing the value of what we have built recognized by the market.</p><p>Thank you for your continued support, patience, and trust. The work continues. The developments are accelerating. And I believe the value we have been building will speak for itself.</p><p>Sincerely,</p><p>Peter Hwang<br/>Chief Executive Officer<br/>OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>)</p><p><strong>About OSR Health, Inc.</strong></p><p>OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.</p><p><strong>Investor Contact</strong></p><p>OSR Health, Inc.<br/>Investor Relations<br/><a rel="nofollow" href="mailto:ir@osr-health.com">ir@osr-health.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company's Nasdaq listing and its efforts to regain compliance, potential out-licensing or strategic transactions involving its subsidiaries and whether any such discussions will be completed, and the development and commercial potential of its businesses. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially, including the risk of delisting, the risk that potential transactions are not completed on favorable terms or at all, and risks relating to clinical development, regulatory approvals, financing, and liquidity, as well as the risk factors described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.</p><p><strong>SOURCE</strong>: OSR Health, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/osr-health-ceo-reaffirms-confidence-and-highlights-subsidiary-business-development-1206049'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1206049" width="0" height="0"/>

OSRH

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health sees licensing interest ahead of Nasdaq listing deadline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Founder and CEO addresses the Company&amp;#39;s Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>OSR Health’s CEO letters ahead of the Aug 18 Nasdaq deadline highlight ongoing listing risk while noting two subsidiaries attracting out-licensing inquiries—one at term sheet and one in early stages. The developments suggest IP and business value validation, potentially unlocking value if licensing progress or listing relief occurs. Management emphasizes execution and patience, signaling near-term catalysts despite a difficult year.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nasdaq listing decision due by Aug 18; risk if price stays below $1.</li><li>Two OSRH subsidiaries inbound for out-licensing; one term sheet, one early-stage.</li><li>CEO cites meaningful IP validation; time will tell sooner rather than later.</li><li>Advancing subsidiary development to preserve Nasdaq listing amid a challenging year.</li><li>Largest investor asserts commitment; continues to invest alongside shareholders.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>OSR Health, Inc. (OSRH)</strong>: Nasdaq-listed; licensing inquiries for subsidiaries; listing risk if price remains sub-$1.</li><li><strong>Nasdaq, Inc. (NDAQ)</strong>: Exchange overseeing listing requirements; context for delisting risk if OSRH price fails to regain $1.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The piece centers on Nasdaq listing status and potential licensing milestones—key catalysts that could influence OSRH&#039;s valuation and liquidity in the near term.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nasdaq listing decision due by Aug 18 creates near-term volatility.</li><li>Two subsidiaries reportedly drawing license inquiries; one term sheet in progress.</li><li>No final license deals yet; OSRH remains cash-burn focused in R&amp;D.</li><li>Largest investor reiterates commitment, signaling insider confidence.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of the press release: August 11, 2026.</li><li>Nasdaq deadline for listing determination: August 18, 2026.</li><li>Two subsidiaries involved in out-licensing discussions; one at preliminary term sheet, another in early stage.</li><li>OSR Health, Inc. ticker: OSRH; company operates as a global healthcare holding company.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term upside possible if Nasdaq listing is preserved or licensing progress accelerates within weeks to months.</p>
  </section>
</section>


<p><i><strong>Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development</strong></i></p> <p><strong id="dateline">BELLEVUE, WA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 11, 2026 / </strong>OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>) today released the following letter from its Chief Executive Officer to shareholders.</p><p>Dear Shareholders,</p><p>Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.</p><p>As CEO of OSRH, I want to assure our shareholders that I remain deeply confident in the fundamental value we are building across our Company and its subsidiaries. I also want to share an important development with the market.</p><p>Without disclosing confidential information or identifying the parties involved at this stage, I can confirm that two of our subsidiaries have received inbound inquiries regarding potential out-licensing opportunities for their technologies and products. Of the two, one is at the preliminary term sheet negotiation phase while the other is in early stage. I believe both of these represent meaningful validation of the value of the intellectual property and businesses that we have worked so hard to develop.</p><p>I fully understand the significance of making this statement as the CEO of a Nasdaq-listed public company. I am making it because I believe our shareholders deserve to know that meaningful business developments are taking place behind the scenes. Time will tell, and I believe that time will tell sooner rather than later.</p><p>As we approach August 18, I respectfully ask our shareholders and long-standing supporters to remain engaged, informed, and supportive of OSRH as we work through this critical period. The Company is doing everything within its control to organically preserve its Nasdaq listing and to ensure that the substantial value being created within our subsidiaries can ultimately be reflected in the market.</p><p>I have also received many messages from shareholders asking why I have not personally purchased additional shares at the current price levels. I want to clarify this point for the market.</p><p>As the largest investor in OSRH, I have been "all in" for a very long time. Since inception, I have committed substantial personal capital through multiple rounds of financing to provide liquidity and support the continued operation of our cash-burning R&D businesses. Anyone who has built a startup from the ground up as a founder will understand what I mean when I say that I am already all in.</p><p>Our journey has never been about building value overnight. We planted the seeds, watered them, nurtured them, and continued investing in them through some extraordinarily difficult circumstances. Our subsidiaries are now entering a period in which their business development activities are accelerating, and we believe the commercial potential of these businesses will become increasingly evident.</p><p>This has undoubtedly been one of the most difficult years in our Company's history, particularly because of the pressure on our share price. But I continue to believe that, ultimately, fundamentals matter. The technologies, intellectual property, people, and businesses that we have built are real-and we intend to continue working relentlessly to unlock their value.</p><p>OSRH is guided by a seasoned management team with deep, complementary experience across biosciences, medical technology, drug development, regulatory, legal and capital markets. This team has both the capability and the resolve to steer the Company through challenging periods such as this one. We have navigated adversity before, and we are confident in our ability to do so again.</p><p>There is still uncertainty ahead, and I will not make promises about outcomes that are not yet within our control. But I can make this promise: we will continue to fight for the Company, for the businesses we have built, and for the interests of our shareholders. I have invested alongside you, I remain invested alongside you, and I remain committed to seeing the value of what we have built recognized by the market.</p><p>Thank you for your continued support, patience, and trust. The work continues. The developments are accelerating. And I believe the value we have been building will speak for itself.</p><p>Sincerely,</p><p>Peter Hwang<br/>Chief Executive Officer<br/>OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>)</p><p><strong>About OSR Health, Inc.</strong></p><p>OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.</p><p><strong>Investor Contact</strong></p><p>OSR Health, Inc.<br/>Investor Relations<br/><a rel="nofollow" href="mailto:ir@osr-health.com">ir@osr-health.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company's Nasdaq listing and its efforts to regain compliance, potential out-licensing or strategic transactions involving its subsidiaries and whether any such discussions will be completed, and the development and commercial potential of its businesses. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially, including the risk of delisting, the risk that potential transactions are not completed on favorable terms or at all, and risks relating to clinical development, regulatory approvals, financing, and liquidity, as well as the risk factors described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.</p><p><strong>SOURCE</strong>: OSR Health, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/osr-health-ceo-reaffirms-confidence-and-highlights-subsidiary-business-development-1206049'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1206049" width="0" height="0"/>

OSR Health’s CEO letters ahead of the Aug 18 Nasdaq deadline highlight ongoing listing risk while noting two subsidiaries attracting out-licensing inquiries—one at term sheet and one in early stages. The developments suggest IP and business value validation, potentially unlocking value if licensing progress or listing relief occurs. Management emphasizes execution and patience, signaling near-term catalysts despite a difficult year.

News insight

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

AI summary

Sentiment rationale

Key facts

Corporate Developments